In 2020, over 1.6 million people reported having an opioid use disorder.
Those are only the reported numbers.
They also only count the US, but opioid addiction is a global crisis.
It’s a problem where the only current “solution” is effectively a dangerous cycle that often leads to worsening outcomes.
Nirvana Life Sciences is a Canada-based pharmaceutical that’s developing psychedelic-derived medical products to combat addiction and pain management with non-addictive solutions.
In other words: we’re finally getting a PRACTICAL solution to the problem!
Problem 👉 Massive Global Costs
Solution 👉 Psychedelics-based Medicines
Advantage 👉 Extraction of Natural Materials & PureAI
Bottom Line 👉 First Mover With Competitive Advantage
For years, the most effective pain management medications marketed by pharmaceuticals and prescribed by doctors have been opioids.
Sure, they do a great job of relieving physical pain, but their highly addictive nature has created a whole new set of problems with devastating consequences for addicts, their families, and the communities they live in.
These consequences come at massive costs to society.
In the US alone, opioid-involved overdose deaths have been on the rise for the last decade with 21,000 deaths in 2010, 47,000 in 2017, and more than 68,000 reported in 2020.
According to the Council of Economic Advisors, the crisis costs the US economy over $500B every year.
You’d think those types of numbers would inspire practical solutions, right?
Wrong: current solutions propose lower-cost (or free) opioids which only serve to strengthen the addiction.
Nirvana is reviving theories developed by researchers in the 1960-70s and applying a modern approach to develop new, psychedelics-based medicines that address addiction as well as the reliance on opioid medicines for pain management.
There’s an entire school of thought—with the body of research to back it up—that believes novel psilocybin formulations could offer fresh, practical approaches to pain management, addiction, anxiety, and depression.
The company is currently conducting pre-clinical trials into the efficacy of psilocybin-based formulations as a therapeutic tool to assist in opioid addiction treatment.
Nirvana’s focus is on aiding patients to transition off highly addictive opioids (“The Relapse” formulation) and providing a non-addictive alternative to pain relief.
Towards this end, they’ve targeted two products that are currently in the first phase of development.
The first assists in preventing relapse and the second delivers non-addictive pain relief. Both are one-per-day, slow-release gel caps.
The reports from the pre-clinical research trials are expected in Q3 at which point the company expects the prototypes for these initial products will enter the next stage of their development process.
While others in the space focus on synthetic materials to create therapeutic compounds, Nirvana prioritizes the extraction of natural materials.
The synthesizing process has been around for years but it’s not cost-effective.
Nirvana is developing a more effective and sustainable way of tryptamine production that will render these old processes obsolete once perfected.
To get there, the company plans to grow several genera and species of fungi with a high standard of quality and batch consistency which they’ll use to extract the active tryptamines from the biomass to yield psilocybin and psilocin in the form of pure crystalline isolate, salts, tinctures, high bioavailable water-soluble liquids, and dry powders.
These products will be sold to other researchers under a Dealer’s License from Health Canada.
At the center of its extraction process is Nirvana’s secret weapon: PureAI.
PureAI is a high-vacuum factional distillation system that should allow the company to achieve separations of non-tryptamine compounds at a lower temperature than conventional fractional systems.
The systems will also allow for the isolation of secondary and tertiary compounds.
These compounds represent enormous potential in the form of further research, new formulations, medicines, and products that will set Nirvana apart in the market.
The best part? Nirvana has acquired an exclusive license to this extraction and distillation technology for the Psychedelics market!
Opioid addiction is a global crisis without a practical solution.
A practical solution is on the horizon and there’s one company that’s got a head start on the rest.
The legalized, medicinal use of psilocin, psilocybin, and other naturally derived tryptamines is a new frontier.
This means there’s an enormous opportunity for Nirvana to seize the market on new FDA-approved formulations.
Armed with a robust portfolio of intellectual property from researchers with vast experience in the psychedelics space, a proven research team, and an exclusive license to game-changing technology, Nirvana represents the best chance to solve the opioid crisis once and for all.
The information contained on this website has been prepared by the paid advertiser Nirvana Life Sciences. The publisher does not guarantee the accuracy or completeness of the information provided in this page. All statements and expressions herein are the sole opinion of the paid advertiser. Nirvana Life Sciences has paid $75,000 to have this content (in addition to other content on other social media sites) created and published. GetVersed is a publisher of financial information, not an investment advisor. We do not provide personalized or individualized investment advice or information that is tailored to the needs of any particular recipient.
The information contained on this website has been prepared by the paid advertiser. The publisher does not guarantee the accuracy or completeness of the information provided in this page. All statements and expressions herein are the sole opinion of the paid advertiser.
Grit Capital Corporation is a publisher of financial information, not an investment advisor. We do not provide personalized or individualized investment advice or information that is tailored to the needs of any particular recipient.
THE INFORMATION CONTAINED ON THIS WEBSITE IS NOT AND SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, AND DOES NOT PURPORT TO BE AND DOES NOT EXPRESS ANY OPINION AS TO THE PRICE AT WHICH THE SECURITIES OF ANY COMPANY MAY TRADE AT ANY TIME. THE INFORMATION AND OPINIONS PROVIDED HEREIN SHOULD NOT BE TAKEN AS SPECIFIC ADVICE ON THE MERITS OF ANY INVESTMENT DECISION. INVESTORS SHOULD MAKE THEIR OWN INVESTIGATION AND DECISIONS REGARDING THE PROSPECTS OF ANY COMPANY DISCUSSED HEREIN BASED ON SUCH INVESTORS’ OWN REVIEW OF PUBLICLY AVAILABLE INFORMATION AND SHOULD NOT RELY ON THE INFORMATION CONTAINED HEREIN. INVESTORS SHOULD OBTAIN INDIVIDUAL FINANCIAL ADVICE BASED ON THEIR OWN CIRCUMSTANCES BEFORE MAKING AN INVESTMENT DECISION.
No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned.
Any projections, market outlooks or estimates herein are forward looking statements and are inherently unreliable. They are based upon certain assumptions and should not be construed to be indicative of the actual events that will occur. Other events that were not taken into account may occur and may significantly affect the returns or performance of the securities discussed herein. The information provided herein is based on matters as they exist as of the date of preparation and not as of any future date, and the publisher undertakes no obligation to correct, update or revise the information in this document or to otherwise provide any additional material.
The publisher, its affiliates, and clients of the publisher or its affiliates may currently have long or short positions in the securities of the companies mentioned herein, or may have such a position in the future (and therefore may profit from fluctuations in the trading price of the securities). To the extent such persons do have such positions, there is no guarantee that such persons will maintain such positions.
Neither the publisher nor any of its affiliates accepts any liability whatsoever for any direct or consequential loss howsoever arising, directly or indirectly, from any use of the information contained herein.